The effectiveness of nirmatrelvir/ritonavir regimen in hospitalized renal transplant patients with prolonged COVID-19 infection: a multicenter clinical experience.
| Title: | The effectiveness of nirmatrelvir/ritonavir regimen in hospitalized renal transplant patients with prolonged COVID-19 infection: a multicenter clinical experience. |
|---|---|
| Authors: | Zhang, Huanxi1 (AUTHOR), Wu, Wenrui1 (AUTHOR), Zheng, Yitao2 (AUTHOR), Fu, Qian1 (AUTHOR), Chen, Peisong3 (AUTHOR), Li, Jianyi1 (AUTHOR), Wu, Zixuan2 (AUTHOR), Gu, Jincui4 (AUTHOR), Li, Jun1 (AUTHOR), Liu, Longshan1,5,6 (AUTHOR), Wu, Chenglin1 (AUTHOR), Long, Sizhe7 (AUTHOR), Xu, Bowen1 (AUTHOR), Ling, Liuting1 (AUTHOR), Fu, Yingxin2 (AUTHOR), Wang, Changxi1,5,6 (AUTHOR) |
| Source: | Renal Failure. Dec2024, Vol. 46 Issue 2, p1-12. 12p. |
| Abstract: | Effectiveness of nirmatrelvir/ritonavir (NR) in kidney transplant recipients (KTRs) infected COVID-19 for more than 5 days has not been evaluated. In this multicenter retrospective study, 85 KTRs with COVID-19 were enrolled, including 50 moderate, 21 severe, and 14 critical patients. The median time from onset to starting NR treatment was 14 (IQR, 11–19) days. Before NR treatment, 96.5% patients reduced use of antimetabolites. They also stopped using calcineurin inhibitors (CNI) 12–24 hours before NR treatment, with CNI concentrations well-controlled during NR treatment. The use of intravenous corticosteroids increased with COVID-19 severity. The median time to reach viral negative conversion was 5 (IQR, 4–8) days for all patients. For moderate and severe COVID-19 patients, they had a low rate of ICU admission (1.4%), exacerbation requiring upgraded oxygen therapy (5.6%), and dialysis (2.8%); no intubation and mechanical ventilation, and no deaths were observed. Patients with critical COVID-19 had a low mortality rate (7.1%). A regimen including NR for clearing SARS-CoV-2 along with reducing immunosuppressants and using intravenous corticosteroids is associated with lower rates of exacerbation and mortality in KTRs who have moderate to critical SARS-CoV-2 infection and the virus still present after 5 days. [ABSTRACT FROM AUTHOR] |
| Copyright of Renal Failure is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Academic Search Complete |
| Full text is not displayed to guests. | Login for full access. |
Be the first to leave a comment!